Abstract
We report results of a Phase I study of a novel immunotherapy we developed based on our described technique for in vitro primary immunization of human peripheral blood mononuclear cells (PBM)
(Biotechniques 1:30, 1983). Twenty patients with metastatic cancer were enrolled in this prospective study (15 renal cell and 1 each of breast carcinoma, glioblastoma, rhabdomyosarcoma, melanoma and transitional cell carcinoma). Patient PBM were depleted of suppressor T-cells and immunized in vitro against autologous tumor antigen. The immunized PBM were then re-infused. Patients received 3 infusions, each of 50-100 × 106 cells. In addition, patients received cimetidine to block suppressor T-cell activation (Lancet I:636, 1981). The only toxicity was fever of 102° in 1 patient following-the second infusion. At this time, 10 patients are available for analysis with regard to therapeutic efficacy. This excludes 5 patients who died prior to their first efficacy evaluation timepoint (3 months) and 5 others who have not yet reached that timepoint. Five of these 10 evaluable patients had an objective clinical response, as evidenced by clinical examination or radiographic study. There was a significant correlation (p<-05) between clinical response and the level of specific anti-tumor antibody that could be measured in patient sera following treatment. We are encouraged by these results, since toxicity appears minimal, and we saw objective evidence of therapeutic efficacy in patients with end-stage metastatic disease.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Osband, M., Carpinito, G., Nuss, R. et al. 928 EFFECTIVE TREATMENT OF METASTATIC CANCER WITH IN VITRO IMMUNIZED AUTOLOGOUS LYMPHOCYTES AND CIMETIDINE. Pediatr Res 19, 265 (1985). https://doi.org/10.1203/00006450-198504000-00958
Issue Date:
DOI: https://doi.org/10.1203/00006450-198504000-00958